disease. Baseline TGF-␤1, diabetes mellitus and serum albumin Low TGF-␤1 serum levels are a risk factor for atherosclerosis levels proved to be the only independent contributors to athdisease in ESRD patients.
The incidence of cardiovascular disease, mainly related is an independent risk factor for cardiovascular diseases, and to atherosclerosis, increases significantly in dialysis paif any correlation exists between TGF-␤1 and any yet known tients, for whom it is the main cause of death [1] . The atherosclerotic risk factors.
relative risk of mortality from ischemic heart disease has Methods. We studied 155 patients who were on regular hebeen estimated as 22 times higher in dialysis patients modialysis, with or without clinically significant atherosclerotic vascular disease. Forty-one apparently healthy people were than in the normal population, a risk similar to that of enrolled as a control group. TGF-␤1 was evaluated during the survivors from a first myocardial infarction. The high midweek dialysis session, at times 0, 30, and 120 minues, at incidence of vascular complications in dialysis patients the end of the session, and 3 hours after the session's end. All also involves peripheral vascular disease and stroke, the hitherto known atherosclerotic risk factors also were evaluated.
high incidence of which likewise is thought to be related
The investigation was performed over a 24-month follow-up. to an acceleration of atherogenesis. It is still controversial In hemodialysis patients, besides the well-known risk also correlated with albumin (r ϭ 0.31). In the coronary heart disease (CHD) group (N ϭ 32) the TGF-␤1 was 26.2 Ϯ factors that can trigger the atherosclerotic process such 4.9 ng/mL; in the cerebrovascular disease (CVD) group (N ϭ as old age, smoking, hypertension, hypercholesterolemia, 8 ) it was 26.7 Ϯ 3.7 ng/mL and in the peripheral vascular disease other factors such as hyperhomocysteinemia, hyperpara-(PVD) group (N ϭ 9) it was 25.4 Ϯ 1.7 ng/mL. In dialysis thyroidism, malnutrition, and inflammation seem to acpatients with no cardiovascular disease (N ϭ 80) TGF-␤1 was celerate the process [4] [5] [6] . However, no combination of 35 .1 Ϯ 6.8 ng/mL (P Ͻ 0.0001 vs. CHD, CVD and PVD pathe known risk factors has provided a convincing explatients). TGF-␤1 was significantly lower among those patients with triple coronary vessel disease than with the other CHD nation of why accelerated atherosclerosis occurs in dialpatients. The Cox analysis demonstrated that a 1 ng/mL reducysis patients [7, 8] . Probably other mechanisms besides tion in TGF-␤1 concentration was associated with a 9% inthese are triggered or accelerated by dialysis therapy or crease in the relative risk of a cardiovascular event.
by persisting uremia, and play an important role. macrophages and by protecting endothelial function [10] [11] [12] . [55] that is activated proteolytically by plasmin [15] . In turn, plasmin is produced from plasminogen by tissue plasminogen activator, the production of which is blocked by own hemodialysis treatment throughout the study. All competitive inhibition from lipoprotein(a) [Lp(a)] and patients were regularly treated three times weekly with plasminogen activator inhibitor 1 (PAI-1). These molestandard bicarbonate dialysis (62%) or hemodiafiltration cules are therefore able to promote smooth muscle cell (38%). The dialyzers used were hemophan (58%), polyproliferation by relieving the inhibition caused by active acrylonitrile (PAN; 12%), and polysulfone (30%). In TGF-␤ [16, 17] . Two kinds of TGF-␤ receptor (types I all procedures the same heparinization modalities were and II) have been identified on target cell membranes, employed: in the washing phase, 2 liters of saline solution both receptors being required for TGF-␤1 signaling to were used containing 20,000 IU of standard heparin in occur [18] .
single pass (Sodic Heparin; Vister by Parke-Davis, PontyThe aims of our present study were to evaluate both pool, UK), followed by 2000 Ϯ 500 IU in a continuous the basal and the intradialytic serum levels of TGF-␤1 intradialytic infusion. in uremic patients and to assess whether TGF-␤1 is an
The distribution of TGF-␤1 values in the population independent risk factor for cardiovascular disease in the per hemodialysis duration quartile is shown in Figure 1 . hemodialysis population studied, checking for any relaBecause there is a known genetic predisposition to be tionship with cardiovascular disease in regular dialysis high, intermediate or low TGF-␤1 producers in both the treatment (RDT) patients. We also assessed for a corredialysis population and the control group [20] , we anlation between TGF-␤1, the acute phase reactants, and alyzed two single-nucleotide polymorphisms in the DNA any known atherosclerotic risk factors.
sequence encoding the leader sequence of the TGF-␤1 protein, located at position ϩ869 (codon 10, T→C, leu-METHODS cine→proline) and position ϩ915 (codon 25, G→C, argiThe study began with a consecutive series of 155 Caunine→proline). The signal peptide sequence, where the casian patients on regular hemodialysis treatment in our studied polymorphisms are located, was cleaved from the dialysis unit. Baseline characteristics of the 88 males and TGF-␤1 precursor at codon 29. The signal sequence al-67 females are reported in Table 1. lowed the new synthesized protein to be exported across Their ages ranged from 30 to 85 years (mean age the membranes of the endoplasmatic reticulum [21, 22] . 62.3 Ϯ 14.2 years). Hemodialysis treatment had been Alteration of the signal sequence, changing one amino initiated 74.3 Ϯ 81.2 months before the baseline TGF-␤1 acid for another, can affect export efficiency. serum level evaluation. All patients were on regular dial-
The putative high haplotypes are T/T G/G and T/C G/G; ysis treatment three times a week; the mean Kt/V (calcuintermediate are T/C G/C, C/C G/G and T/T G/C; low lated according to Daurgirdas' second logarithmic forproducers are C/C G/C, C/C C/C, T/T C/C and T/C C/C. mula) was 1.3 Ϯ 0.3 [19] ; the diuresis was Ͻ200 mL/day Seventy-five patients (49%) from among the 155 selected patients of our dialysis centre had a history or for all the patients. Patients were maintained on their their clinical history. Nonetheless, all these patients were examined by vascular Doppler echography to exclude significant and still silent atherosclerotic involvement of these arteries, or the presence of atherosclerotic plaques. evidence of one or more "atherosclerotic related" proAbdominal aorta, carotid arteries and iliac-femoral arcesses on entry to our study (Table 2) . Clinically signifiteries were the vascular districts observed. cant atherosclerotic vascular disease was defined as the Platelet basal levels did not differ between the dialypresence of coronary heart disease (CHD), cerebrovassis patients with and without atherosclerotic diseases cular disease (CVD), or peripheral vascular disease (PVD) (230,000 Ϯ 23,000/mmc vs. 227,000 Ϯ 27,000/mmc, P ϭ as described in what follows. NS) nor between 14 patients with severe CHD and 18 Coronary heart disease was diagnosed by at least one patients with mild CHD (223,000 Ϯ 28,000/mm 3 vs. of the following criteria: (1) previous admission for docu-228,000 Ϯ 22,000/mmc, P ϭ NS). mented myocardial infarction, not later than three months Of the 155 patients selected, 88 (56.6%) suffered from before the study started (elevated creatine kinase level hypertension for which they were on antihypertensive and electrocardiogram changes); (2) a clinical history of treatment. Only 15 patients (9.6%) were receiving angiosymptoms consistent with angina confirmed by a positive tensin-converting enzyme (ACE) inhibitors, 6 with ramiexercise stress test result; or (3) significant positive repril 5 Ϯ 0 mg/day, and 9 with enalapril 10 Ϯ 5.5 mg/day. sults on coronary angiograms (stenosis Ͼ50% for 1 of Forty-one apparently healthy people, comparable in the 3 major vessels) or on thallium scan (defining fixed age (63 Ϯ 11 years) and sex distribution (21 males and or reversible perfusion defects). In these patients CHD 20 females), were enrolled as a control group for TGF-␤1 was diagnosed on the basis of their previous clinical and serum level. This latter group also underwent an electroinstrumental backgrounds: these patients had undergone cardiogram (ECG) and vascular Doppler echography, with thallium scan (30 patients) or coronary angiograms (25 the same criteria, to exclude ischemic myocardial disease patients) at least once prior to entry in the study. and atherosclerotic disease. In these patients no pathoCerebrovascular disease was defined by at least one logical signs were found by the tests. All of the Doppler of the following criteria: (1) a previous stroke (acuteechography tests were performed by the same radiologist. onset irreversible neurological deficit) not later than Platelet basal levels did not differ between the control three months before the study started, documented by group and the dialysis patients, with and without atherocerebral CT or MRI or by a physician in the patient's sclerosis: (238,000 Ϯ 34,000/mmc vs. 230,000 Ϯ 23,000/ medical records, or (2) evidence of stenosis Ͼ50% for mmc, P ϭ NS, and 238,000 Ϯ 34,000/mmc vs 227,000 Ϯ carotid vessels at Doppler echography. Peripheral vascu-28,000/mmc, P ϭ NS, respectively). lar disease was defined by the presence of claudicatio intermittens, previous peripheral vascular surgery (7 paLaboratory methods tients), including amputation for ischemic limb (3 paThe TGF-␤1 serum level was evaluated immediately tients), or the presence of atherosclerotic plaques at Doppler echography or at abdominal-iliac-femoral angibefore and during the midweek session; blood samples at the end of the session, and three hours afterwards. During the same dialysis session a fasting blood sample was drawn to check low-density lipoprotein (LDL-C), triglycerides (TG), lipoprotein(a) [Lp(a)], homocysteine, albumin, C-reactive protein (CRP), fibrinogen, and plasused in conjuction with the D-mix, and 5 U/L of the minogen activator inhibitor type 1 (PAI-1) from all parecombinant Taq polymerase (Perkin-Elmer Amplitaq tients. Sampling was only performed at the dialysis start DNA Polymerase). The final reaction volume was 10 L. (time 0). LDL-C, TG, albumin, CRP, fibrinogen and ho-
The amplification program was run on a Perkin-Elmer mocysteine were evaluated by standard laboratory meth-9700 thermalcycler: 1 cycle of 96ЊC for 130 seconds, 63ЊC ods; Lp(a) was evaluated by an immunometric method for 60 seconds; 9 cycles of 96ЊC for 10 seconds, 63ЊC for (Bouty Inc., Sesto S, Giovanni, Italy), PAI-1 was evalu-60 seconds, 20 cycles of 96ЊC for 10 seconds, 59ЊC for 50 ated by a chromatogenic method (Dade Behring Inc.
seconds, 72ЊC for 30 seconds. PCR products were visualMilan, Italy). We used a Genomic Prep Blood DNA ized on a 2.5% agarose gel stained with ethidium broIsolation Kit (Pharmacia Biotech, Inc., Uppsala, Swemide. den). The dosage of TGF-␤1 was made as follows: first The protocol was approved by an Ethics Committee a serum separator tube was used to allow the sample to and informed consent was obtained from all the patients. clot for one hour at room temperature. In order to obtain Follow-up studies a complete release of TGF-␤1, blood samples were maintained overnight at 2 to 8ЊC before centrifugation. Then
The investigation was based on a prospective study enthe samples were centrifuged at 1000 ϫ g for 10 minutes, tailing 24 months of follow-up. The requirement for paand the serum obtained was stored at Ϫ70ЊC. To convert tients to return to our dialysis unit three times a week any inactive TGF-␤1 to an active form, the samples were facilitated the determination of clinical and laboratory first acidified (by adding 100 L of a 2.5 N acetic acid/10 findings associated with baseline TGF-␤1 levels during mol/L urea solution to 100 L of serum) and then restored the follow up. to pH 7.2 to 7.6 by 100 L of a 2.7 N NaOH/1 mol/L Date and cause of death were recorded directly for HEPES solution.
deaths occurring in our Unit and from interviews with the Concentrations were determined by means of a solid physicians who verified the cause when death occurred phase, TGF-␤1-specific sandwich enzyme-linked immuoutside the dialysis unit. nosorbent assay (ELISA) (Quantykine; R&D Systems, The cause of death was classified as a cardiovascular Minneapolis, MN, USA). The minimum detectable level event (myocardial infarction, sudden death, and stroke) of TGF-␤1 was 7 pg/mL. or non-cardiovascular event (infection, neoplasms, masThe genotype polymorphism was determined as folsive gastrointestinal bleeding, others including uncertain lows: blood from all individuals was collected in sterile causes when no clear atherosclerotic event was found). tubes containing 0.1% of ethylenediaminetetraacetic acid (EDTA); genomic DNA was extracted using a GeStatistical analysis nomic Prep Blood DNA Isolation Kit (Pharmacia BioStatistical analysis was performed by the Statistical tech. Inc.). DNA samples were screened for mutations Package for the Social Sciences (SPSS for Windows in the TGF-␤1 gene by polymerase chain reaction (PCR) Software Package; version 9.0.1). Data are presented as single strand polymosphism (SSP) methodology with the means Ϯ standard deviation. Cytokine Genotyping Tray Kit (One Lambda Inc., Los
The Student t test was used for group comparison of Angeles, CA, USA). Pre-optimized primers were precontinuous variables with normal population distribusented, dried in different wells of a 96-well 0.2-mL thintion (Kolmogorov-Smirnov test, Z ϭ 0.77). walled tube tray for PCR and made ready for the addi-
The ANOVA test was performed to evaluate the intra tion of DNA samples, recombinant Taq polymerase, and and post-dialytic behavior of serum TGF-␤1 (Table 3) . specially formulated dNTP-buffer mix (D-Mix). Each Linear regression analysis was performed to evaluate tray included a negative control reaction tube and an the presence of a statistically significant relationship beinternal control PCR product, amplified from the hutween two parameters, in this case between TGF-␤1 and man-globin gene. The amount of the primer was adjusted for optimal amplification of 100 ng of sample DNA when the other baseline variables commonly known as risk producers, 25.2 Ϯ 11.0 ng/mL, and the 8 (5%) low producers, 26.5 Ϯ 9.2 ng/mL (Table 4 ). In the control group, the same percentage distribution of dialysis patients was found: 33 (80%) patients were high producers, 6 (14%) were intermediate and 2 (5%) low producers. Because a certain number of our hemodialysis patients had clinical evidence of atherosclerosis on entry to the study, the TGF-␤1 levels were compared among the three groups of CHD, CVD and PVD patients (Table 5 ). In the CHD group (N ϭ 32), the TGF-␤1 level was 26.2 Ϯ 4.9 ng/mL, in the CVD group (N ϭ 8) 26.7 Ϯ 3.7 ng/mL and in the PVD (N ϭ 9) 25.4 Ϯ 1.7 ng/mL (P ϭ NS). In hemodialysis patients with no evidence of cardiovascular disease the TGF-␤1 mean value was 35.1 Ϯ 6.8 ng/mL (P Ͻ 0.0001 vs. CHD, CVD and PVD patients). Interestingly, in patients with simultaneous evidence of CHD, CVD and PVD disease (N ϭ 20), TGF-␤1 was significantly lower (mean 16.7 Ϯ 4.0 ng/mL; P Ͻ 0.0001 again versus those with CHD, CVD or PVD alone). Furthermore, the TGF-␤1 serum concentration was significantly lower (20 Ϯ 3 ng/mL) among those patients of the CHD group with triple coronary vessel disease (N ϭ 14) than among patients of the same group with mild CHD (N ϭ 18), whose serum concentration was 30.8 Ϯ 5 ng/mL, P Ͻ 0.001 (Fig. 3) . Transforming growth factor-␤1 serum levels were again nearly the same in hypertensive patients (25.2 Ϯ 8.4 ng/mL) versus non-hypertensives (28.4 Ϯ 9.3 ng/mL) and in diabetics (25.4 Ϯ 8.7 ng/mL) versus non-diabetics factors for atherosclerosis: age, sex, LDL-C, TG, Lp(a), (26.9 Ϯ 9.0 ng/mL), and they did not correlate with the homocysteine, albumin, CRP, fibrinogen, and PAI-1. different causes of end-stage renal disease. Multivariate analysis was performed using the Cox From the analysis of the association of TGF-␤1 baseproportional hazard model to determine the indepenline serum levels with other potential risk factors for dent association of baseline parameters with the risk of atherosclerotic clinical events, no significant correlation cardiovascular death during the follow-up period. Variwas found between TGF-␤1 and LDL-C, TG, homocysables entered in the final analysis were: age, diabetes, teine and fibrinogen (Table 2) . A weak inverse correlasystolic arterial pressure, dyastolic arterial pressure, tion emerged between TGF-␤1 and age (r ϭ Ϫ0.28), LDL, TGF-␤1 and albumin.
TGF-␤1 and Lp(a) (r ϭ Ϫ0.35), TGF-␤1 and CRP (r ϭ Kaplan-Meier event-free survival curves were ana-Ϫ0.27) and, finally, between TGF-␤1 and PAI-1 (r ϭ lyzed separately on the two groups with TGF-␤1 serum Ϫ0.41); TGF-␤1 also proved to correlate with albumin level respectively above and below the mean value (r ϭ 0.31). In the population studied a positive moderate 26.64 ng/mL. correlation also was found between CRP and albumin (r ϭ 0.63) and CRP and Lp(a) (r ϭ 0.52).
Transforming growth factor-␤1 serum levels were RESULTS evaluated before the start of the midweek dialysis sesBaseline findings sion, separating patients dialyzed with hemophan (24.8 Ϯ The mean TGF-␤1 concentration in our hemodialysis 7.4 ng/mL) from those on PAN (mean value 26.5 Ϯ 5.4 patients was 26.6 Ϯ 7 ng/mL compared with 42.3 Ϯ ng/mL) and those on polysulfonee (27.7 Ϯ 9.3 ng/mL). 6 ng/mL in the control group (P Ͻ 0.0001; Fig. 2 
). No
No statistically significant difference was found either significant difference in TGF-␤1 was found between among the three groups of membranes or between the males (25.2 Ϯ 10.5 ng/mL) and females (28.1 Ϯ 6.8 two techniques (standard bicarbonate dialysis 25.8 Ϯ 5.4 ng/mL) among the hemodialysis population. ng/mL vs. hemodiafiltration 26.9 Ϯ 4.7 ng/mL). Checking Again in the dialysis group, no significant difference the intradialytic behavior of TGF-␤1 serum levels, only in TGF-␤1 was found between the 129 (83%) high proat 30 minutes was there a significant reduction (by about 30%, P Ͻ 0.001), without any difference reflecting the ducers, 27.2 Ϯ 8.0 ng/mL, the 18 (11%) intermediate membrane or the technique used (Fig. 4 and Table 3 ). By three hours after the session's end, levels had reverted to basal values (Fig. 4) . (17 cardiovascular and 1 non-cardiovascular; Table 6 ). Three patients discontinued dialysis treatment after renal transplantation. risk of cardiovascular death. Baseline TGF-␤1, serum Age, LDL, systolic arterial pressure, diastolic arterial albumin and the presence of diabetes mellitus levels pressure, male sex, diabetes, albumin and TGF-␤1 levels proved the only independent contributors to risk in the were entered into the stepwise logistic regression analysis as variables to determine their contribution to the regression model (Table 7) . cated. In the first quartile there were 9 deaths (28.6%), in the second high values group (Ͼ26.64 ng/mL; solid line) and the TGF-␤1 low values quartile 7 (18.5%), in the third there was 1 death (6.7%), in the fourth group (Ͻ26.64 ng/mL; dashed line) was P Ͻ 0.001 by the log rank test.
quartile with the highest TGF-␤1 levels no death occurred.
The Cox analysis demonstrated that a 1 ng/mL reduc-DISCUSSION tion in TGF-␤1 concentration was associated with a 9%
The importance of cardiovascular disease in RDT paincrease in the relative risk of undergoing a cardiovastients emerges from both clinical and statistical evaluacular event (P ϭ 0.04). The presence of diabetes (P ϭ tions that show the precocity and the impact of athero-0.04) and hypoalbuminemia (P ϭ 0.02) were the only sclerotic disease on dialysis patients in terms of morbidity parameters that contributed to the regression model. and mortality. Finally, using the mean TGF-␤1 concentration value
No combination of Framingham risk factors has proof 26.64 ng/mL as an arbitrary cut off value to define vided a convincing explanation of why dialysis patients patients with higher and lower TGF-␤1 values, the Kaphave accelerated atherosclerosis. lan-Meier survival curves were calculated separately.
Recently several experimental studies in non-renal paThe Kaplan-Meier survival curves showed significant tients have focused on the role cytokines may play in gendifferences between the two groups: P Ͻ 0.001 by the log erating atherosclerosis. Artherosclerotic changes could rank test (Fig. 5) .
be partly an expression of an imbalance between antiTo confirm the Kaplan-Meier survival curves, mortalatherogenic (TGF-␤1) and atherogenic (MCSF and IL-6) ity histograms for quartiles of TGF-␤1 levels were procytokines and growth factors [11] [12] [13] [14] . vided (Fig. 6) . Cut-off values for quartiles were TGF-␤1
Transforming growth factor-␤1 is a pleiotropic proconcentrations of 19.7 ng/mL, 26.7 ng/mL and 32.8 ng/mL. tein. Some of its effects are the result of its neutralizing The data demonstrated that the higher the TGF-␤1 value, the main inflammatory cytokines by inhibiting their synthe lower the percentage of deaths: in the first quartile thesis [as with tumor necrosis factor-alpha (TNF-␣)] or there were 9 deaths (28.6%), in the second quartile 7 by downscaling their effects (as with IL-1␤, interferon-␥ (18.5%), in the third there was one death (6.7%), and and TNF-␣) [23, 24] . in the fourth quartile with the highest TGF-␤1 levels no Evidence also exists that TGF-␤1 down-regulates (1) the inflammatory cytokine-induced expression of VCAM-1, death occurred.
(2) the leukocyte adhesion to the endothelium, and (3) deprove to be predictive of cardiovascular mortality. Some creases macrophage activity by releasing IL-1 Ra [25] [26] [27] .
protective role is surely posited if we reflect that a reducTransforming growth factor-␤1 has four actions to (1) tion by 1 ng/mL of TGF-␤1 is associated with a 9% inhibit both migration and proliferation of smooth musincrease in the risk of mortality. cle cells and macrophages [15, 28] ; (2) induce apoptosis
The main result that emerges from our study is that in numerous cells involved in the vascular lesions [29, 30] ; our RDT patients had a significantly lower concentration (3) reduce adhesiveness of the endothelium for inflamof active TGF-␤1 than the control group of healthy submatory cells [15, [31] [32] [33] ; and (4) contribute to vascular jects. The low TGF-␤1 serum levels in our RDT patients protection by inhibiting human metalloelastase identiexclude the possibility that the two investigated genetic fied in vulnerable areas of plaque and responsible for its patterns of production may ultimately affect TGF-␤1 instability [34] . serum levels. Indeed, the low-producer prevalence in These experimental backgrounds have been confirmed our populations is only 5%. by several clinical studies. In particular, Grainger et al
The most significantly lowered levels occurred in pafound that serum levels of active TGF-␤1 were more setients with simultaneous evidence of coronary, cerebral verely depressed in non-renal patients with advanced athand peripheral vascular disease. Among the patients with erosclerosis than in persons without coronary atheroscleischemic heart disease, the lowest levels were found in rosis [11] . McDonald et al found that increased serum those with significant stenoses of three major coronary TGF-␤1 may exert a cardioprotective effect [35] . Subsevessels. These results are in agreement with previous quently Erren et al confirmed that TGF-␤1 serum levels reports regarding non-renal patients with so-called triple are low in patients with severe ischemic heart disease [13] .
vessel disease [11, 14] . In RDT patients, Suthanthiran et al found higher levSuch a correlation between reduced TGF-␤1 levels and els of serum TGF-␤1 in black than in white patients, and ischemic heart disease is related both to the antiproliferasuggested that this may be associated with the reduced tive effect of this cytokine on SMC and to its specific incidence among the former of ischemic heart disease and cardioprotective effect. TGF-␤1 is able to counteract death from myocardial infarction, and that this may exthe release of TNF-␣ into the blood after myocardial plain the observation that blacks survive better than ischemia via a transcription and translation mechanism whites on hemodialysis [36] . Grainger et al also found [45] . TGF-␤1 also reduces superoxide production in the that (active ϩ latent) TGF-␤1, and the proportions of ischemic coronary circulation by its endothelium pro-TGF-␤1 that were active, were similar in serum and tecting effect, which it also achieves by suppressing leukoplatelet poor plasma prepared from the same blood samcyte adhesion to endothelial cells even in the presence ples [37]. Tashiro found significantly lower TGF-␤1 of inflammatory cytokines. plasma levels in patients with ischemic heart disease than
The cardiovascular protecting effect of TGF-␤1 is all in controls [14] .
the more important considering that the cells targeted Research into the role of TGF-␤1 in atherosclerotic by TGF-␤1 come under the effect of other growth factors and restenotic processes has given conflicting results.
such as PDGF-AB and MCSF, which interact with speSeveral articles indicate that TGF-␤1 tends to be highly cific receptors promoting proliferative activity and thus expressed at sites of vascular injury, particularly in hucounteract the effects of TGF-␤1. To further complicate man restenotic lesions [38, 39] . Conversely other authors this broad scenario, our previous papers reported the sigmaintain that TGF-␤1 is a potent antiproliferative agent nificant intradialytic platelet release of PDGF-AB that for vascular cells [40, 41] and that decreased activation might predispose RDT patients to atherosclerosis [46, 47] . of TGF-␤1 is associated with the progression of atheroUnfortunately, the patients we studied had no ascersclerosis [11] .
tained TGF-␤1 levels for the pre-dialytic period, so we The differing pattern of expression of TGF-␤1 recepwere unable to clarify if and how its concentration varied tors may hold a key to understanding the role of TGF-␤1 as hemodialysis treatment got underway. in the atherosclerotic process [30] .
The absence of a TGF-␤1 inhibitory effect [42, 43] in TGF-␤ and traditional atherosclerotic risk factors the end leads to increased chemotaxis, increased extraAmong the traditional atherosclerotic risk factors, age cellular matrix formation, cell proliferation and a decrease seems to affect basal TGF-␤1 values only partially. In in apoptosis. Thus, the resistance to apoptosis may lead our study there was only a weak inverse correlation of to the slow proliferation of cell subsets resistant to TGF-␤1 levels with age occurring both for hemodialyis TGF-␤1, thereby contributing to the progression of athpatients (with or without cardiovascular diseases) and erosclerotic or restenotic lesions [30, 31, 44] .
for the control group. There are no conclusive data in the TGF-␤ and cardiovascular disease literature on any correlation between age and TGF-␤1 in non-renal patients [11] . This may be due to the shortage Using a stepwise multiple regression analysis, only low TGF-␤1 levels, apart from diabetes and serum albumin, of studies on the subject.
No statistically significant difference in TGF-␤1 levels ratio 1.1). Again, among hemodialysis patients with cardiovascular disease, albumin shows a significant, though emerges from our study between males and females among our hemodialysis patients. By contrast in nonmoderate, direct correlation with serum TGF-␤1 levels. In our view, this result lends itself to at least to two interrenal patients the TGF-␤1 serum level is thought to be correlated with gender. Grainger in particular speculates pretations that need not be mutually exclusive: (1) both parameters reflect the severity of vascular impairment that women's TGF-␤1 levels may be under hormonal regulation, especially considering the ascertained secretion and/or the degree of vascular inflammation; (2) as with hypoalbuminemia, low TGF-␤1 values might express a of TGF-␤1 from fetal human fibroblasts by antiestrogens [11] . Clearly, more extensive studies are needed to define state of malnutrition. Among the acute phase proteins, Lp(a) is thought to the role of gender and age on TGF-␤1 levels.
The incidence of diabetes mellitus in our population correlate in part with an inhibition of TGF-␤1 activation [16, 53] . In accordance with previous reports our mean was around 5%. Among the evaluated cardiovascular risk factors, diabetes proved to have a higher role in values of Lp(a) prove higher in patients with known cardiovascular disease than other RDT patients or the terms of mortality (odds ratio 3.38) in our study population. However, no statistical difference emerged between control group [54] [55] [56] . Our results show a slight inverse correlation between Lp(a) and TGF-␤1. This does not diabetics and non-diabetics where TGF-␤1 levels were concerned.
seem sufficient in itself to account for the reduced basal serum levels of TGF-␤1. It is well-known that high levels of LDL and reduced levels of HDL are associated with an increased risk of It is possible, however, that the inflammatory process inside the arterial wall enhances the pathophysiological cardiovascular mortality. Grainger finds an inverse correlation between serum LDL cholesterol and the proporeffects of Lp(a), thus further reducing the activation of TGF-␤1 [57] . In this connection we found a slight tion of active TGF-␤1, and proposes that the sequestration of TGF-␤1 to lipoprotein represents a possible correlation between Lp(a) and PCR. Plasminogen activator inhibitor-1 is a 50 kD protein mechanism for depression of TGF-␤1 activity in advanced atherosclerosis [48] .
synthesized and released by endothelial cells. High PAI-1 levels have been shown to predict the risk of recurrent If we look at our own patients, no correlation between LDL and TGF-␤1 values was found; indeed, patients myocardial infarction in younger non-uremic men and the occurrence of ischemic accidents in atherosclerotic with the highest survival on dialysis show the highest levels of LDL. Again, the multivariable regression model patients [58] . PAI-1 production can be stimulated by oxidized LDL and cytokines such as TNF, both of which did not show any statistically significant correlation between total serum cholesterol or LDL concentration and are elevated in hemodialysis patients [17] . The proatherogenic role of PAI-1 also is probably linked to its cardiovascular disease. As with total serum cholesterol, we did not find any significant association between sysproperty of blocking the activation of latent TGF-␤1 by competitively inhibiting tPA. PAI-1 and Lp(a) promote tolic blood pressure and cardiovascular disease. The fact that multivariable analysis showed no association be-SMC proliferation in culture by reducing the autocrine inhibition caused by active TGF-␤1 [59, 60] . tween the serum total cholesterol level or systolic blood pressure and the presence of atherosclerotic cardiovasIn agreement with previous observations [61, 62] , PAI-1 values in our hemodialysis patients proved higher than cular disease is at first sight somewhat surprising, but in line with the results of other cohort studies [7, 8] . These among controls. The increase was more marked in cardiovascular patients. These results could be related to observations once again raise questions as to whether the traditional cardiovascular risk factors are applicable the high plasma cytokine levels found in hemodialysis patients and the degree of endothelium dysfunction. In to the chronic hemodialysis population.
our study PAI-1 levels showed a moderate inverse corre-TGF-␤, albuminemia, and acute phase reaction lation with TGF-␤1 levels. These results seem to confirm the experience of other authors with non-renal patients, The finding that hypoalbuminemia predicts death in dialysis patients has been attributed to inflammation, that is to say, a moderately inhibiting effect by PAI-1 on TGF-␤1 exists. This effect might combine with the malnutrition and underdialysis [49] . Some authors have recently found a link between both CRP and hypoalbumsimilar inhibition by Lp(a) and partly explain the low TGF-␤1 values. inemia and cardiovascular disease in both the general population and in hemodialysis patients (abstract; Bergs-TGF-␤ and the hemodialysis procedure trö m et al, J Am Soc Nephrol 6:573, 1995) [50] [51] [52] .
In our study the serum albumin levels are significantly Neither the type of membrane [cellulose modified (HE) or synthetic (PAN, PS)] nor the technique used lower in hemodialysis patients with cardiovascular disease, and this correlates with CRP levels: albumin emerges as seemed to affect the basal serum TGF levels, there being no significant differences among the membranes or the an independent risk factor for cardiovascular death (odds patients to a worsening of atherosclerosis, in agreement with what has been argued in non-renal patients. Hemodialysis patients with severe cardiovascular disease showed a negative moderate correlation of TGF-␤1 with raised techniques used. These findings would appear to dislevels of Lp(a) and PAI-1 and a moderate direct correlacount the possibility of TGF-␤1 basal values and the tion with serum albumin levels. From the multivariable activation pathway being somehow related to the biologanalysis it emerged that TGF-␤1 is an independent carical reaction directly caused by the blood-membrane condiovascular risk factor along with diabetes and hypotact, or this result being considered an expression of albuminemia. Nonetheless, if we consider that reduced higher or lower biocompatibility of the artificial materi-TGF-␤1 levels also have been found in hemodialysis als. Our results are broadly in line with Suthanthiran's patients without cardiovascular disease, we can argue in vivo study that found no significant difference between that the observed correlations are not the only possible "biocompatible" and "bioincompatible" membranes [36] .
explanation of such a change in hemodialysis patients. On the other hand, they diverge from the Mege et al's Therefore, the low TGF-␤1 levels also could be hypoin vitro experience [63] .
thetically related to (1) subclinical endothelium damage, The intradialytic behavior of TGF-␤1 serum levels or (2) heparin-mediated activation of TGF-␤1, which showed a marked reduction at 30 minutes (about 30%) might lead to a reduction in TGF-␤1 serum values (exwith a progressive return to basal values three hours haustion) as a consequence of the subsequent link beafter the session's end and without any difference related tween TGF-␤1 and the TGF-␤1 receptor. Nevertheless, to the membrane and/or technique used. Though we reduced TGF-␤1 levels still only can be considered a have no proper explanation for this result, we do think necessary, and not a sufficient, condition. The role of that removal across the dialyzer membrane may be ruled TGF-␤1 in atherosclerosis needs further evaluation and out in view of the high molecular weight of this growth correlation with other known risk factors by means of factor. However, the biology and the activation pathway longer prospective controlled studies. of TGF-␤1 might well hold the key to interpreting the result. In the circulation TGF-␤1 exists in two distinct, ACKNOWLEDGMENT biologically inactive forms: the original latent complex and a second complex with the protease inhibitor ␣ 2 -
